Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's a big day for Mesoblast Ltd (ASX: MSB) shares today.

Not because shares in the clinical-stage biotechnology company are gaining again. In fact, they're headed the other direction on Friday, down 8.1% in early afternoon trade at $1.635 apiece.

There's no need to break out your tiny violin for longer-term stockholders, though. As you can see on the chart below, Mesoblast shares remain up an eye-watering 427% in 2024.

Created with Highcharts 11.4.3Mesoblast PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

Rather, today is a big day for the company because Mesoblast hosted its annual general meeting (AGM) this morning.

Here's what the company's top management had to say.

Mesoblast shares in focus amid AGM

"This year has seen our company make significant advances as a leading developer of innovative allogeneic cellular medicines," chair Jane Bell said.

She noted:

[Mesoblast has] an extensive clinical-stage pipeline of therapeutic assets validated by clinical data that address serious and life-threatening inflammatory illnesses. Our key areas of focus remain cardiovascular disease, chronic low back pain, and acute life-threatening inflammatory conditions including graft versus host disease (GvHD)…

2024 has been pivotal in our journey toward commercialising our therapies.

Bell said that the company's "positive interactions" with the United States Food and Drug Administration (FDA) enabled Mesoblast to resubmit the Biologics License Application for approval of Ryoncil (remestemcel-L).

The product is intended to help children with steroid-refractory acute GvH.

"As the current review for approval of Ryoncil progresses," Bell added, "our focus has turned to implementing the commercialisation strategies that will allow us to successfully launch Ryoncil, a much-needed treatment for desperately ill children, upon FDA approval."

In addition, the ASX biotech company is working towards filing for accelerated FDA approval of Revascor (rexlemestrocel-L) in end-stage heart failure patients.

As for the balance sheet, Bell noted:

Our balance sheet has been well-managed, including recently securing access to US$50 million to fund our planned commercial launch on approval of Ryoncil, while at the same time maintaining financial discipline through the implementation of cost reduction strategies to maximise our financial runway.

Looking at what might impact Mesoblast shares in the year ahead, Bell said, "As we plan for 2025 and beyond, I am very optimistic about Mesoblast's future."

She added, "The strength of our science, the dedication of our impressive team, and the support of our shareholders position us to achieve our goal of delivering transformative therapies to patients in need."

CEO Silviu Itescu reiterated that Mesoblast "expects to substantially advance its multiple product pipeline" toward FDA approvals over the next six to 12 months.

On the cost reduction front, which has helped support Mesoblast shares, Itescu highlighted the 26% year-on-year decline in the company's net operating cash spend for the September quarter.

Should you invest $1,000 in Mesoblast Limited right now?

Before you buy Mesoblast Limited shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Mesoblast Limited wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 7 February 2025

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Woman flexes muscles after donating blood.
Healthcare Shares

The CSL share price hit a 52-week low this week. Is it time to buy?

Is this beaten-up biotech a healthy opportunity?

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Sigma share price up 9% on first day of trading post-merger with Chemist Warehouse

It's a post-merger party for Sigma Healthcare shareholders today.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Up 135% in a year, why this ASX 200 healthcare stock is 'on track to become a truly great Australian success'

A leading fund manager expects more strong performance from this surging ASX 200 healthcare stock.

Read more »

Stethoscope with a piggy bank in the middle.
Healthcare Shares

With revenue up 9%, why does the NIB share price keep falling?

Will the ailing share price make a full recovery?

Read more »

Six smiling health workers pose for a selfie.
Healthcare Shares

Guess how much $5,000 invested in Sigma shares in December 2023 is worth now!

Sigma shares have soared over the past year alongside the merger with Chemist Warehouse.

Read more »

Woman with headphones on relaxing and looking at her phone happily.
Healthcare Shares

Everything you need to know about the latest CSL dividend

CSL's latest dividend should be turning investors' heads...

Read more »

thoughtful investor sitting at computer
Healthcare Shares

What are brokers saying about CSL shares after the selloff?

The biotech giant's shares hit a 52-week low yesterday. Is this a buying opportunity?

Read more »

A man looking at his laptop and thinking.
Earnings Results

CSL shares push higher despite 'mixed result with headline misses'

There were positives and negatives in the company's first half performance.

Read more »